Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

分组1 - Crinetics Pharmaceuticals, Inc. reported a quarterly loss of $1.29 per share, which was better than the Zacks Consensus Estimate of a loss of $1.37, representing an earnings surprise of +6.01% [1] - The company posted revenues of $6.16 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 38.05%, compared to zero revenues a year ago [2] - The stock has underperformed, losing about 6.8% since the beginning of the year, while the S&P 500 has gained 1.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is -$1.25 on revenues of $7.61 million, and for the current fiscal year, it is -$5.05 on revenues of $62.05 million [7] - The Zacks Industry Rank for Medical - Drugs is in the bottom 44% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8]